Cargando…

A high-throughput expression screening platform to optimize the production of antimicrobial peptides

BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Christine, Müller, Hagen, Birrenbach, Oliver, Klein, Moritz, Heerd, Doreen, Weidner, Tobias, Salzig, Denise, Czermak, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307881/
https://www.ncbi.nlm.nih.gov/pubmed/28193216
http://dx.doi.org/10.1186/s12934-017-0637-5
_version_ 1782507452925739008
author Schreiber, Christine
Müller, Hagen
Birrenbach, Oliver
Klein, Moritz
Heerd, Doreen
Weidner, Tobias
Salzig, Denise
Czermak, Peter
author_facet Schreiber, Christine
Müller, Hagen
Birrenbach, Oliver
Klein, Moritz
Heerd, Doreen
Weidner, Tobias
Salzig, Denise
Czermak, Peter
author_sort Schreiber, Christine
collection PubMed
description BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing for the identification of suitable expression constructs, we have developed a small-scale expression screening platform based on a combinatorial plasmid library. RESULTS: The combinatorial library is based on the Golden Gate cloning system. In each reaction, six donor plasmids (each containing one component: a promoter, fusion partner 1, fusion partner 2, protease cleavage site, gene of interest, or transcriptional terminator) were combined with one acceptor plasmid to yield the final expression construct. As a proof of concept, screening was carried out in Escherichia coli and Pichia pastoris to study the expression of three different model AMPs with challenging characteristics, such as host toxicity or multiple disulfide bonds. The corresponding genes were successfully cloned in 27 E. coli and 18 P. pastoris expression plasmids, each in a one-step Golden Gate reaction. After transformation, small-scale expression screening in microtiter plates was followed by AMP quantification using a His(6) tag-specific ELISA. Depending on the plasmid features and the expression host, the protein yields differed by more than an order of magnitude. This allowed the identification of high producers suitable for larger-scale protein expression. CONCLUSIONS: The optimization of recombinant protein production is best achieved from first principles by initially optimizing the genetic construct. The unrestricted combination of multiple plasmid features yields a comprehensive library of expression strains that can be screened for optimal productivity. The availability of such a platform could benefit all laboratories working in the field of recombinant protein expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0637-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5307881
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53078812017-03-13 A high-throughput expression screening platform to optimize the production of antimicrobial peptides Schreiber, Christine Müller, Hagen Birrenbach, Oliver Klein, Moritz Heerd, Doreen Weidner, Tobias Salzig, Denise Czermak, Peter Microb Cell Fact Research BACKGROUND: Antimicrobial peptides (AMPs) are promising candidates for the development of novel antibiotics, but it is difficult to produce sufficient quantities for preclinical and clinical studies due to their toxicity towards microbial expression hosts. To avoid laborious trial-and-error testing for the identification of suitable expression constructs, we have developed a small-scale expression screening platform based on a combinatorial plasmid library. RESULTS: The combinatorial library is based on the Golden Gate cloning system. In each reaction, six donor plasmids (each containing one component: a promoter, fusion partner 1, fusion partner 2, protease cleavage site, gene of interest, or transcriptional terminator) were combined with one acceptor plasmid to yield the final expression construct. As a proof of concept, screening was carried out in Escherichia coli and Pichia pastoris to study the expression of three different model AMPs with challenging characteristics, such as host toxicity or multiple disulfide bonds. The corresponding genes were successfully cloned in 27 E. coli and 18 P. pastoris expression plasmids, each in a one-step Golden Gate reaction. After transformation, small-scale expression screening in microtiter plates was followed by AMP quantification using a His(6) tag-specific ELISA. Depending on the plasmid features and the expression host, the protein yields differed by more than an order of magnitude. This allowed the identification of high producers suitable for larger-scale protein expression. CONCLUSIONS: The optimization of recombinant protein production is best achieved from first principles by initially optimizing the genetic construct. The unrestricted combination of multiple plasmid features yields a comprehensive library of expression strains that can be screened for optimal productivity. The availability of such a platform could benefit all laboratories working in the field of recombinant protein expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0637-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-13 /pmc/articles/PMC5307881/ /pubmed/28193216 http://dx.doi.org/10.1186/s12934-017-0637-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schreiber, Christine
Müller, Hagen
Birrenbach, Oliver
Klein, Moritz
Heerd, Doreen
Weidner, Tobias
Salzig, Denise
Czermak, Peter
A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title_full A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title_fullStr A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title_full_unstemmed A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title_short A high-throughput expression screening platform to optimize the production of antimicrobial peptides
title_sort high-throughput expression screening platform to optimize the production of antimicrobial peptides
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307881/
https://www.ncbi.nlm.nih.gov/pubmed/28193216
http://dx.doi.org/10.1186/s12934-017-0637-5
work_keys_str_mv AT schreiberchristine ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT mullerhagen ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT birrenbacholiver ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT kleinmoritz ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT heerddoreen ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT weidnertobias ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT salzigdenise ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT czermakpeter ahighthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT schreiberchristine highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT mullerhagen highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT birrenbacholiver highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT kleinmoritz highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT heerddoreen highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT weidnertobias highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT salzigdenise highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides
AT czermakpeter highthroughputexpressionscreeningplatformtooptimizetheproductionofantimicrobialpeptides